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ABSTRACT 
Recently, we developed a technique that allows the in uiuo visu- 
alization in man of somatostatin receptor-positive neuroendocrine 
tumors after iv injection of [iZ31-Tyr3]octreotide or [“‘In-DTPA-n- 
Phe’loctreotide. Radiotherapy of such tumors using somatostatin an- 
alogs coupled to OL- or P-emitting radionuclides has been proposed as 
an application for radiolabeled somatostatin analogs. To develop this 
concept further, it is of importance to know whether the above-men- 
tioned radiolabeled somatostatin analogs are internalized by the tu- 
mor cells, and whether it might be possible to manipulate the degree 
of internalization. In the present study we investigated the internal- 
ization of a stable somatostatin analog, [‘251-Tyr3]octreotide, by 
mouse AtT20/D16V pituitary tumor cells and primary cultures of 
human GH-secreting pituitary tumor cells. Treatment of the cells 
with low pH was used to distinguish between membrane-bound 
(acid-releasable) and internalized (acid-resistant) radioligand. 
[‘““I-Ty?Joctreotide showed a time-dependent increasing accumu- 
lation in AtTPO cells; after 4 h of incubation, values up to 6-S% of the 
dose of radioligand added were obtained. Binding and internalization 
of [‘“51-Tyr310ctreotide were temperature dependent and inhibited by 
pertussis toxin. Inhibitors of lysosomal degradation did not increase 
the amount of internalized radioligand. After 4 h of incubation, 88% 
of the radioactivity present in the cells was still peptide bound, sug- 
gesting a low intracellular breakdown of this radioligand. Six of seven 
human GH-secreting adenoma cell cultures also internalized [iz51- 
Tyr3Joctreotide (variation between 0.24-4.98% of the dose radioli- 
gand added). Displacement of binding and internalization of [lz51- 
Tyr3Joctreotide by unlabeled octreotide showed a bell-shaped curve in 
AtT20 cells. At low concentrations (0.1 and 1 nM), binding and inter- 
nalization were increased, whereas at higher concentrations, satu- 
ration occurred. In contrast to this, binding of [‘251-Tyr3Joctreotide to 
a broken cell preparation of AtT20 cells was displaced in a dose- 
dependent manner by unlabeled octreotide, with an IC,, of 0.1 nM. 
Similar observations were made in the human GH-secreting adenoma 
cell cultures. 
In conclusion, a high amount of [ i2”I-Tyr3]octreotide is internalized 
in a specific-, time-, temperature-, and pertussis toxin-sensitive GTP- 
binding protein-dependent manner by mouse AtT20 and human GH- 
secreting pituitary tumor cells. In the presence of a low concentration 
of unlabeled octreotide, a rapid increase in the amount of [i2”I- 
Tyr3Joctreotide internalized by AtT20 cells and by the majority of the 
human GH-secreting adenoma cell cultures was found. Because mem- 
brane binding was simultaneously increased, this is suggested to be 
related to a rapid recruitment of somatostatin receptors at the outer 
tumor cell membrane. (Endocrinology 136: 3698-3706, 1995) 
S OMATOSTATIN receptors (SS-R) are present in all nor- mal target tissues of the peptide, such as brain, anterior 
pituitary gland, and pancreas. In a variety of human tumors, 
frequently originating from normal somatostatin (SS) target 
tissues, high numbers of SS-R can be detected by classical 
biochemical binding techniques as well as by in vitro auto- 
radiography. These tumors include those with amine pre- 
cursor uptake and decarboxylation characteristics (pituitary 
tumors, endocrine pancreatic tumors, carcinoids, paragan- 
gliomas, small cell lung cancers, medullary thyroid carcino- 
mas, and pheochromocytomas) as well as meningiomas, well 
differentiated brain tumors (astrocytomas), neuroblastomas, 
lymphomas, and some human breast cancers (1). Recently, 
we developed a technique that allows the in viva visualiza- 
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tion in man of the above-mentioned SS-R-positive tumors 
after iv injection of [iz31-Tyr3]octreotide (2,3) or [“‘In-DTPA- 
u-Phe’loctreotide (4). Using this technique, we showed that 
certain tumors, especially those with a high number of SS-R, 
could be visualized 48 h after injection (l-4). This rather long 
residence time of radioactivity on human tumors in viuo 
suggests that the radioligand is internalized by the tumor 
cells. Internalization of radioligand is of special importance 
when radiotherapy of certain SS-R-positive human cancers 
with CX- or p-emitting isotopes coupled to SS analogs is 
considered (5, 6). 
At present, equivocal data have been reported with respect 
to internalization of SS. Receptor-mediated endocytosis of SS 
has been demonstrated in rat anterior pituitary cells and rat 
islet cells (7-14), whereas other investigators found that [lz51- 
Tyr’]SS-14 and [‘251-Tyr”]SS-14 are not rapidly internalized 
by GH,C, rat pituitary cells and RINm5F insulinoma cells, 
respectively, probably due to degradation of these radioli- 
gands at the cell surface (15, 16). As data with respect to 
internalization of SS may have been influenced by the sus- 
ceptibility to degradation of the SS ligands used in the above- 
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mentioned studies, investigations with respect to internal- 
ization of more stable radioligands, such as [“‘I- 
Tyr3]octreotide (17), may provide a better insight into the 
amount of internalization by SS-R-positive (tumor) cells. 
In the present study, therefore, we investigated whether 
the stable SS analog [125 I-Tyr”]octreotide is internalized by 
SS-R-positive AtT20/D16V mouse pituitary tumor cells and 
human GH-secreting pituitary tumor cells. We recently 
found that accumulation of [“‘In-DTPA-o-Phe’]octreotide 
in SS-R-positive organs showed a tissue-specific bell-shaped 
function of the injected mass of the radiopharmaceutical (18). 
To investigate the cellular mechanisms underlying these ob- 
servations, we also studied the effect of different concentra- 
tions of unlabeled octreotide on binding and internalization 
of [‘2”I-Tyr3]octreotide by the two cell culture systems. 
Materials and Methods 
Cell culture 
AtT20/D16V mouse pituitary tumor cells were obtained from Dr. J. 
Tooze (European Molecular Biology Organization, Heidelberg, Germa- 
ny). The cells were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with sodium pyruvate (1 mM), 10% fetal calf serum, 
fungizone (0.5 mg/liter), penicillin (10” U/liter), and sodium bicarbon- 
ate (2.2 g/liter, final concentration). The medium was adjusted to pH 7.4 
with 1 N NaOH. The cells were passaged once a week using trypsin 
(0.05%) and EDTA (0.02%). For internalization experiments, the cells 
were seeded at a density of 0.5 x 10h cells/well in 12.well multiwell 
plates (Costar, Cambridge, MA) and grown to confluency for 2 days. 
Human GH-secreting pituitary tumor tissue from seven acromegalic 
patients was obtained by transsphenoidal operation. A single tumor cell 
suspension was prepared by enzymatic dispersion of the tissue, as 
described in detail previously (19). For internalization experiments, the 
tumor cells were cultured for 4 days at a density of 10 cells/3 ml in 
12-well multiwell plates (Costar) in Minimal Essential Medium supple- 
mented with nonessential amino acids, sodium pyruvate (1 mM), 
10% fetal calf serum, penicillin (lo-5 U/liter), fungizone (0.5 mg/liter), 
L-glutamine (2 mM), and sodium bicarbonate (2.2 g/liter, final concen- 
tration). The medium was adjusted to pH 7.4 with 1 N NaOH. 
The effect of 10 nM act-eotide on GH release was investigated in all 
GH-secreting pituitary adenoma cultures (10s cells/well). Experimental 
conditions and determination of the GH concentration in the medium 
by immunoradiometric assay were described previously (20). 
All cells were cultured at 37 C in a water-jacketed incubator in hu- 
midified air with 5% CO,. The media and supplements were obtained 
from GIBCO (Paisley, UK). 
Radioligands 
The SS analoe 
iodinated with “. 
[Tyr”Joctreotide (Sandoz, Basel, Switzerland) was 
I by the chloramine-T method and purified by HPLC, 
as described previously in detail (21). The specific radioactivity of the 
radioligand was approximately 2000 Ci/mmol. 
Internalization experiments 
On the day of the experiment, AtT20 cells were washed twice with 
internalization medium. The internalization medium consisted of Dul- 
becco’s Modified Eagle’s Medium supplemented with HEPES (30 mM), 
L-glutamine (2 mM), sodium pyruvate (1 mM), penicillin (10s U/liter), 
fungizone (0.5 mg/liter), and 0.2% BSA (fraction V, Sigma Chemical Co., 
St. Louis, MO). The medium was adjusted to pH 7.4 with 1 N KOH. The 
cells were allowed to adjust to the medium for 1 h at 37 C. Thereafter, 
approximately 200,000 cpm [‘Z’I-Tyr’Joctreotide f-0.1 nM, final con- 
centration) were added to the medium, and the cells were incubated at 
37 C for other temperatures when indicated) for a period of up to 4 h 
in quadruplicate without or with excess unlabeled octreotide (1 PM) to 
determine nonspecific membrane binding and internalization. Binding 
and internalization of J”sI-Tyr’loctreotide were blocked by excess un- 
labeled octreotide (Sandoz Pharma, Basel, Switzerland), whereas unre- 
lated peptides, such as LHRH (1 FM; Hoechst, Amsterdam, The Neth- 
erlands) and TRH (1 PM; Hoechst), had no effect. In some experiments 
the cells were pretreated with pertussis toxin (Sigma) for 18 h and with 
chloroquine (Sigma) or NH,Cl for 30 min. 
Treatment of the cells with low pH was used to distinguish between 
membrane-bound (acid-releasable) and internalized (acid-resistant) ra- 
dioligand (22). After the incubation, the cells were washed twice with 
ice-cold internalization medium. Thereafter, 1 ml sodium acetate (20 
mM) in Hanks’ Balanced Salt Solution, pH 5.0 (HBSS-AC), was added to 
the cells. The cells were then incubated for 10 min at 37 C. After 10 min, 
the supernatant was collected. Finally, the cells were washed with HBSS- 
AC, and the supernatant was pooled with the supernatant of the previous 
step. This pooled supernatant fraction, acid-extractable radioactivity, 
represents membrane-bound radio&and. At the end of the incubation, 
after the HBSS-AC treatment, the cells were extracted in 1 N NaOH. The 
radioactivity in this fraction represents internalized radioligand. 
In one of the experiments, AtT20 cells were broken by freezing in 
liquid nitrogen, and the binding characteristics of [“~I-Tyr’Joctreotide 
to this broken cell 
1: ization of J”s’I-Tyr 
reparation were compared to binding and internal- 
loctreotide by viable AtT20 cells. 
Human GH-secreting pituitary tumor cells that had attached to the 
bottom of the wells during the 4-day culture (see above) were rinsed 
twice with internalization medium. One milliliter of this medium was 
then added to the cells, and incubations were performed as described for 
the AtT20 cells. Both cell types studied remained viable in internalization 
medium during the 4-h incubation period, as determined by trypan blue 
exclusion. 
Intracellular radioactivity was analyzed by Sep-Pak C,, reverse phase 
extraction cartridges (Waters Associates, Milford, MA), as described 
previousiy (23J: 
SS-R binding studies 
SS-R binding studies were carried out using [‘ZSI-Tyr’Joctreotide as 
radioligand, as described previously (24). Rat brain cortex or AtT20 cell 
membrane preparations (corresponding to 15-30 kg protein) were in- 
cubated in a total volume of 100 ~1 at room temperature for 60 min with 
30,000-50,000 cpm radioligand and increasing concentrations of unla- 
beled octreotide in HEPES buffer (10 mM HEPES, 5 mM MgC&, and 0.2 
g/liter bacitracin, pH 7.6) containing 0.2% BSA (Sigma). After the in- 
cubation, 1 ml ice-cold HEPES buffer was added to the assay mixture, 
and membrane-bound radioactivity was separated from unbound by 
centrifugation for 2 min at 14,000 rpm in an Eppendorf microcentrifuge. 
The remaining pellet was washed twice with HEPES buffer, and the final 
pellet was counted in a y-counter. Specific binding was taken to be total 
binding in the absence of excess unlabeled octreotide minus nonspecific 
binding in the presence of excess (1 PM) unlabeled octreotide. Unrelated 
compounds (TRH, LHRH, and epidermal rowth factor), added in a 
IOOO-fold excess, were not able to displace [ I’sI-Tyr?Joctreotide binding. 
Epidermal growth factor was obtained from Saxon Biochemicals 
(Hannover, Germany). 
Analysis of data 
Statistical analysis of the data was performed using one-way analysis 
of variance. When significant overall effects were obtained by analysis 
of variance, multiple comparisons were made by the Newman-Keuls test 
(25). The data are expressed as the mean ? SE of at least three inde- 
pendent experiments or as the mean ? SE of four wells per time point 
or treatment group. IC,, values for displacement of [‘*‘I-Tyr’loctreotide 
binding were determined by the computerized program GraphPad 
[GraphPad, ISI Software, Philadelphia, PA]. 
Results 
Internalization of [‘251-Tyr.‘3]octreotide by mouse AtT20 
pituitary tumor cells 
Scatchard analysis of [‘251-Tyr”]octreotide binding to 
AtT20 cell membranes revealed a high number of high 
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affinity SS-R (2815 + 317 fmol/mg membrane protein; K, = 
0.35 + 0.05 nM; values are the mean 2 SE of four independent 
determinations). 
To verify that the method of separation of internalized 
(acid-resistant) and membrane-bound extracellular (acid-re- 
leasable) ligand indeed released all binding of radioligand 
from membrane receptors, rat brain cortex membranes were 
incubated with [1251-Tyr3]octreotide for 1 h at 20 C without 
or with excess unlabeled octreotide to determine nonspecific 
binding. Thereafter, the membranes were washed twice with 
ice-cold binding buffer and subsequently incubated for 10 
min at 37 C with HBSS-HAc, as described in Materials and 
Methods. The acid treatment completely abolished specific 
binding of [1251-Tyr3]octreotide, demonstrating that all 
membrane-bound radioligand is acid releasable. 
Figure 1 shows time-dependent increasing specific mem- 
brane binding and internalization of [1251-Tyr3]octreotide by 
AtT20 cells. The amount of [1251-Tyr310ctreotide internalized 
was approximately 5% of the dose of radioligand added after 
240 min of incubation, and at all time points studied was 
significantly higher than the amount of radioligand that was 
membrane bound. 
Internalization of [1251-Tyr3]octreotide by AtT20 cells was 
tern 
of P 
erature dependent. At 0 C, no binding or internalization 
[ 251-Tyr3]octreotide was seen, whereas the amount of 
internalized radioligand increased with increasing temper- 
ature (20 and 37 C, respectively; Fig. 2). 
Displacement of binding of [12”I-Tyr”]octreotide to AtT20 
cells at 37 C showed a bell-shaped curve (Fig. 3, A and B). At 
lower concentrations of unlabeled octreotide (0.1 and 1 nM), 
the amounts of both membrane-bound (Fig. 3A) and inter- 
nalized (Fig. 3B) radioligand were significantly increased 
compared to those in control cells, whereas at higher con- 
centrations, unlabeled octreotide saturation occurred. In con- 
trast to the observations with viable AtT20 cells, unlabeled 
octreotide displaced binding of [1251-Tyr3]octreotide to a 
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FIG. 1. Time course of membrane binding and internalization of 11z51- 
Ty?loctreotide (0, membrane bound; 0, internalized) by AtT20 
mouse pituitary tumor cells. Values are expressed as specific binding 
and internalization (percentage of the dose of radioligand added) and 
are the mean + SE of three independent experiments. 
0 c 20 c 37 c 
temperature 
FIG. 2. Temperature dependency of internalization and membrane 
binding of [‘z51-Ty?loctreotide by AtT20 mouse pituitary tumor cells. 
Values are expressed as specific binding and internalization (per- 
centage of the dose of radioligand added) after 4 h of incubation and 
are the mean 2 SE of four wells per treatment group. 0, Membrane- 
bound radioligand; W, internalized radioligand. ND, Undetectable. 
broken cell preparation of AtT20 cells in a dose-dependent 
fashion, with an IC,, of 0.1 nM (Fig. 3C). 
The increased internalization of [1251-Tyr”]octreotide in- 
duced by this low amount (1 nM) of unlabeled octreotide 
occurred very rapidly (Fig. 4). Unlabeled octreotide (1 PM) 
completely blocked internalization of the radioligand by 15 
min of incubation (P < 0.01 us. control cells), whereas 1 nM 
octreotide nearly doubled internalization at this time point (P 
< 0.01 ‘us. control cells). Because the increased internalization 
seems to occur very rapidly, we also studied the effect of 1 
nM unlabeled octreotide at several time points between O-2.5 
min of incubation. The results of these experiments are 
shown in Fig. 5. Again, 1 nM unlabeled octreotide induced a 
very rapid (within 1 min of incubation) 2-fold increase in 
the amount of internalized radioligand (Fig. 5, lower panel). 
At the same time, the amount of membrane-bound [1251- 
Tyr”]octreotide was significantly increased (Fig. 5, upper 
panel). 
To further investigate the mechanism of internalization of 
[1251-Tyr3]octreotide, AtT20 cells were preincubated with 
pertussis toxin or inhibitors of lysosomal degradation, chlo- 
roquine and NH&l. Table 1 shows that pertussis toxin sig- 
nificantly inhibited both membrane binding and the subse- 
quent internalization of [1251-Tyr3]octreotide, indicating that 
this process acts via a pertussis toxin-sensitive GTP-binding 
protein-dependent mechanism. Chloroquine, an inhibitor of 
lysosomal degradation, significantly inhibited internaliza- 
tion of the radioligand. NH&l, another inhibitor of lysoso- 
ma1 function, did not significantly affect internalization, 
however (data not shown). It seems, therefore, that there is 
no major degradation of the radioligand after 4 h of incu- 
bation. This is further substantiated by analysis of intracel- 
lular radioactivity by Sep-Pak C,, reverse phase cartridges in 
cells that had been incubated for 4 h with [1251- 
Tyr3]octreotide. This showed that 88% of the radioactivity 
within the cells was still peptide bound. 
 at Medical Library Erasmus MC on December 18, 2006 endo.endojournals.orgDownloaded from 
INTERNALIZATION OF [ 1251-Tyr3]OCTRE@I’IDE 3701 
B 
c 
1 
. 
I
0 0 01 0.1 1 10 100 
[octreotlde] (nM) [octreotide] (nM) [octreotide] (nM) 
FIG. 3. Bell-shaped function of displacement by increasing concentrations of unlabeled octreotide of membrane-bound (A) and internalized (B) 
[‘zsI-Tyr3]octreotide by AtT20 pituitary tumor cells and displacement of binding of 1 ‘251-Tyr310ctreotide by unlabeled octreotide to a broken cell 
preparation of AtT20 cells (C). In the experiment shown in C, the cells were broken by freezing in liquid nitrogen before incubation with 
[iz51-Tyr3]octreotide under the same conditions as in A and B. Values are expressed as a percentage of specific binding or internalization in 
control cells and are the mean ? SE of four wells per treatment group. Values for control cells were 0.16 ? 0.4% (A), 4.02 + 0.15% (B), and 1.91 
+ 0.49% (C) of the dose of radioligand added. **, P < 0.05; *, P < 0.01 [us. control cells (0 nM)]. 
0.24 
0 30 60 90 120 150 160 210 240 
time (min.) 
FIG. 4. Effect of 1 FM and 1 nM unlabeled octreotide on internaliza- 
tion of [iz51-Tyr3]octreotide by mouse AtT20 pituitary tumor cells. *, 
P < 0.01, 1 nM or 1 FM octreotide US. control cells. Values are expressed 
as a percentage of the dose of radioligand added and are the mean ? 
SE of three independent experiments. 0, Control cells; a, 1 pM oct- 
reotide; 0, 1 nM octreotide. 
Internalization of [‘“51-Tyr3]octreotide by human 
GH-secreting pituitary adenoma cells 
Similar to the observations in AtT20 cells, human GH- 
secreting pituitary adenoma cells from patient 1 showed 
a time-dependent specific membrane binding (Fig. 6, upper 
panel) and internalization of 1’251-Tyr310ctreotide (Fig. 6, 
lower panel). In the presence of 1 nM unlabeled octreotide, 
a rapid increase in both membrane-bound and internal- 
ized radioligand was observed. A statistically significant 
higher amount of radioligand was bound and internalized 
at all time points studied. After 60 min of incubation, an 
approximately 6-fold higher amount of radioligand was 
bound and internalized in the presence of 1 nM unlabeled 
octreotide compared to that in control cells (specific bind- 
ing of control cells, 0.2% VS. 1.3% at 1 nM octreotide; spe- 
cific internalization by control cells, 0.4% us. 2.5% at 1 nM 
octreotide). The total amounts of radioligand bound and 
V.“” - 
0.00 0.50 1.00 1.50 2.bo 2.so 
time (min.) 
FIG. 5. Rapid increase in membrane binding (upper panel) and in- 
ternalization (lozuer panel) of [ ‘““I-Tyr3]octreotide induced by 1 nM 
unlabeled octreotide. 0, Control; 0, 1 nM unlabeled octreotide. *:, P < 
0.01 vs. control cells. Values are expressed as specific binding and 
internalization (percentage of the dose of radioligand added) and are 
the mean 2 SE of three independent experiments. 
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TABLE 1. The effects of pertussis toxin (PT) and chloroquine on 
binding and internalization of [ ““I-Tyrsloctreotide by mouse 
AtTPO pituitary tumor cells 
[‘“‘I-Tyr310ctreotide (7~ of dose) 
Membrane bound Internalized 
Control 0.30 2 0.04 6.39 2 0.15 
PT (100 pg/liter) 0.14 -c 0.03” 3.47 k 0.05” 
PT (500 fig/liter) 0.14 f 0.04” 2.93 2 0.19” 
Chloroquine (100 pM) 0.37 k 0.02 2.12 k 0.10” 
The cells were pretreated for 16 h with PT and for 30 min with 
chloroquine. Thereafter, the cells were incubated for 4 h with 0.1 nM 
[‘z51-Ty?loctreotide without or with the test substances. Parallel 
incubations with excess unlabeled octreotide (1 FM) were performed 
to determine nonspecific binding and internalization. Separation of 
membrane-bound and internalized radioligand was performed as de- 
scribed in Muteri& and Methods. Values represent specific binding 
and internalization (percentage of the dose of radioligand added) and 
are the mean 2 SE of four wells per treatment group. 
n P < 0.01 US. control. 
internalized by these GH-secreting pituitary adenoma 
cells after 4-h incubation were also high (1.28% and 4.98% 
of the dose of radioligand added, respectively). 
The effect of 1 nM unlabeled octreotide was further inves- 
tigated in six other GH-secreting adenoma cell cultures. Ta- 
ble 2 shows that the amount of internalized radioligand was 
significantly increased (32-122% increase) by 1 nM octreotide 
in five of six cultures (no. 1, 4, 5, 6, and 7), which showed 
internalization of the radioligand, whereas the amount of 
membrane-bound radioligand was simultaneously in- 
creased in three of six cultures (no. 1, 6, and 7; 30-113% 
increase). Cultured cells from patient 3 showed no binding 
and internalization, whereas 1 nM octreotide significantly 
lowered internalization by the cultured cells of patient 2. 
Comparable to the findings in AtT20 cells, displacement of 
internalization of [‘251-Tyr3]octreotide by cells of patient 4 
showed a bell-shaped curve, with a maximal increase by 1 nM 
unlabeled octreotide and saturation at higher octreotide 
concentrations (not shown). 
Interestingly, we found that the preoperative SC adminis- 
tration of 50 pg octreotide induced a significant lowering of 
serum GH levels in patients 1 and 2, whereas patients 3 and 
4 showed no response of GH levels to octreotide in viva (Fig. 
7). In support of this sensitivity to octreotide in vim, we 
observed that GH release by cultured cells from patients 1 
and 2 was significantly more sensitive to octreotide in vitro 
than that by cultured tumor cells from patients 3 and 4. GH 
release by cultured tumor cells from patients 1,2,3, and 4 was 
inhibited by octreotide (10 nM) by 83 + 9%, 43 + 2%, 27 t 
l%, and 16 + 0%, respectively. GH release by cells of 
patients 5,6, and 7 was inhibited by 43 k l%, 25 k l%, and 
27 + l%, respectively. Thus, the cells of patients 1 and 5, 
which showed a high amount of internalization of [1251- 
Tyr3]octreotide, also showed a high responsiveness of GH 
release to octreotide in vitro. 
Discussion 
A variety of human neuroendocrine tumors contain recep- 
tors for the tetradecapeptide SS (1). The presence of SS-R on 
these tumors enabled us to develop a technique that allows in 
s 
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.z 
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FIG. 6. Effects of 1 FM and 1 nM unlabeled octreotide on membrane 
binding (upper panel) and internalization (lower panel) of [iz51- 
Ty?]octreotide by human GH-secreting pituitary adenoma cells of 
patient 1. **, P < 0.05; *, P < 0.01 (us. control cells). Values are 
expressed as a percentage of the dose of radioligand added and are the 
mean t SE of four wells per treatment group. 0, Control cells; 0,l FM 
octreotide; A, 1 nM octreotide 
viva visualization in man of SS-R-positive tumors using the 
radiolabeled SS analogs [‘231-Ty?]octreotide and [“‘In-DTPA- 
o-Phe’]octreotide (2-6). In several tumors (i.e. carcinoids and 
paragangliomas) that express a high amount of SS-R, binding 
of radioactivity in viva exceeds estimates of 0.1% of the admin- 
istered dose per g tumor tissue. Radiotherapy using SS analogs 
coupled to (Y- or p-emitting isotopes has been proposed as an 
application for radiolabeled SS analogs and has recently been 
carried out in one patient (5, 6, 26). To develop this concept 
further, it is of importance to know to what extent the above- 
mentioned radiolabeled SS analogs are internalized by SS-R- 
positive tumor cells, and whether it is possible to manipulate 
the degree of internalization. 
In the present study we demonstrated a specific time- and 
temperature-dependent high amount of internalization of 
[‘251-Tyr3]octreotide by mouse AtT20 pituitary tumor cells. 
Binding and internalization were inhibited by pertussis 
toxin, demonstrating that a pertussis toxin-sensitive GTP- 
binding protein is involved in these processes. A previous 
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TABLE 2. The effect of 1 nM unlabeled octreotide (Octr) on the 
amount of membrane-bound and internalized [iz51-Tyreloctreotide 
by human GH-secreting pituitary adenoma cell cultures 
Patient 1’2’I-Tyr”10ctr (R of dose) 
NO. Treatment Membrane bound Internalized 
1 Control 1.28 2 0.18 4.98 2 0.35 
Gctr (1 nM) 2.73 k 0.33” 9.66 k 0.73” 
2 Control 0.48 k 0.02 0.60 k 0.00 
Gctr (1 nM) 0.43 2 0.11 0.40 2 0.04” 
3 Control Not detectable Not detectable 
Gctr (1 KIM) 
4 Control 0.08 k 0.00 0.41 k 0.02 
Gctr (1 nM) 0.09 k 0.00 0.58 k 0.02” 
5 Control 0.58 2 0.02 2.46 2 0.14 
Gctr (1 nM) 0.67 2 0.08 3.25 2 0.17” 
6 Control 0.13 k 0.02 0.24 i- 0.03 
Octr (1 nM) 0.22 2 0.01” 0.51 k 0.05” 
7 Control 0.23 k 0.01 0.73 -t 0.02 
Gctr (1 nM) 0.30 2 0.01” 1.62 2 0.03” 
GH-secreting pituitary adenoma cells (lo61 from seven acromegalic 
patients were incubated for 4 h with 0.1 nM [‘z51-Ty?]Octr without 
or with 1 nM unlabeled Octr. Parallel incubations with excess unla- 
beled Octr (1 PM) were performed to determine nonspecific binding 
and internalization. Separation of membrane-bound and internalized 
radioligand was performed as described in Materials and Methods. 
Values represent specific binding and internalization (percentage of 
the dose of radioligand added) and are the mean t SE of four wells per 
treatment group. 
a P < 0.01 US. control. 
study showed that pertussis toxin reduced the affinity of 
SS-R for SS (and its structural analogs) in AtT20 cells (27). In 
addition, internalization of [‘251-Tyr3]octreotide by human 
GH-secreting pituitary tumor cells was found. Several stud- 
ies have demonstrated receptor-mediated endocytosis of SS 
in rat anterior pituitary cells (7, 9, 11, 12), rat islet cells (10, 
14), and AtT20 cells (8). Other investigators, however, 
showed that [iz51-Tyr’]SS-14 and [‘251-Tyr”]SS-14, unlike 
[‘251]epidermal growth factor, are not rapidly internalized by 
GH,C, rat pituitary cells and RINm5F insulinoma cells, re- 
spectively (15, 16). These investigators suggested that the 
radioligands they used were rapidly degraded by membrane 
proteases. From our present study, it is clear that a high 
amount of the radioiodinated SS analog Tyr”-octreotide is 
internalized by AtT20 mouse and human GH-secreting pi- 
tuitary tumor cells. This is probably related to the high sta- 
bility of [‘251-Tyr3]octreotide (17). The parental cyclic oc- 
tapeptide analog octreotide (SMS 201-995) was shown to be 
highly resistant to degradation by pure enzymes and tissue 
homogenates (28). In agreement with this, we found that 
most of the radioactivity present in the cells after 4 h of 
incubation was still peptide bound, although we did not 
perform HPLC analysis to demonstrate that the peptide- 
bound radioactivity represented intact radioligand. In 
addition, inhibitors of lysosomal degradation (chloroquine 
and NH&l) did not increase the amount of acid-resistant 
(internalized) radioactivity. In fact, in agreement with a pre- 
vious study by Presky and Schonbrunn (15), chloroquine 
FIG. 7. Effect of the administration of 50 Fg octreotide, SC, on serum 
GH levels in four acromegalic patients. 0, Placebo at 0815 h; 0,50 Fg 
octreotide, SC, at 0815 h. 
significantly inhibited the amount of internalized radioli- 
gand. It appears, therefore, that the inhibitory effect of chlo- 
roquine is due to direct interference with the process of 
receptor-mediated endocytosis, and that this latter effect pre- 
vails over its inhibitory effect on lysosomal function under 
the conditions of our study. Our data favor further devel- 
opment of the concept of radiotherapy using radiolabeled SS 
analogs. 
Another finding of our present study is the rapidly in- 
creasing binding and internalization of [‘251-Tyr310ctreotide 
when AtT20 cells and human GH-secreting adenoma cells 
are simultaneously incubated with a low concentration of 
unlabeled octreotide. Displacement of binding and internal- 
ization of radioligand by AtT20 cells by unlabeled octreotide 
showed a bell-shaped curve at 37 C. An increase was found 
at low unlabeled octreotide concentrations (0.1 and 1 nM), 
whereas at higher concentrations, saturation was observed. 
In contrast to this, displacement of binding by unlabeled 
octreotide to a broken cell preparation of AtT20 cells showed, 
under the same incubation conditions, a dose-dependent 
inhibition curve with an IQ,, of 0.1 nM, in agreement with the 
estimated K, of the SS-R on these cells. This suggests that 
binding of [‘251-Tyr310ctreotide to viable cells is a dynamic 
process and may, therefore, show binding characteristics 
different from those of binding to broken cells or a membrane 
homogenate preparation. 
The increased internalization occurred very rapidly. 
Within 1 min of incubation, 1 nM unlabeled octreotide caused 
 at Medical Library Erasmus MC on December 18, 2006 endo.endojournals.orgDownloaded from 
3704 INTERNALIZATION OF [‘““I-Tyr”]OCTREOTIDE Endc . 1995 
Vol 136. No 9 
an increase in the amount of binding and internalization of 
[‘2”I-Tyr”]octreotide by AtT20 cells. In addition, increased 
internalization in the presence of 1 nM unlabeled octreotide 
was found in five of six cultures of human GH-secreting 
pituitary tumors. In three of these human GH-secreting ad- 
enoma cell cultures, this increased internalization was ac- 
companied by an increase in the amount- of- membrane- 
bound radioligand, which suggests a very rapid increase in 
the number of SS-R on these cells. 
There are several studies concerned with the homologous 
regulation of SS-R expression. In GH,C, cells, Presky and 
Schonbrunn (22) demonstrated a time-dependent increase in 
[‘2”I-Tyr’]SS-14 binding by the addition of unlabeled SS-14, 
which reached a maximum of approximately 200% after 20 
h. Other investigators (29,30) showed a decrease in SS bind- 
ing by AtT20 cells after preincubation for 4 h with SS-14 or 
SS-28. In 7315b rat prolactinoma cells, chronic exposure (up 
to 5 weeks) results in a reversible down-regulation of SS-R 
(31). In an earlier study, Schonbrunn and Tashjian (32) 
showed in GH,C, cells a dose-dependent displacement of 
binding of [‘251-Tyr’]SS by unlabeled SS. Therefore, it has to 
be established whether apart from AtT20 and human GH- 
secreting pituitary adenoma cells, other cell types respond to 
unlabeled octreotide with an increased binding and inter- 
nalization of radioiodinated [Tyr”]octreotide. In our study 
we also found that unlabeled SS-14 and SS-28 induced this 
increase in AtT20 cells (data not shown). 
At present, we have no explanation for the mechanism of 
the increased binding and subsequent internalization of [12’1- 
Tyr”]octreotide by AtT20 tumor cells and human GH-secret- 
ing adenoma cells induced by simultaneous incubation with 
a low concentration of unlabeled octreotide. The rapid in- 
crease in [‘2”I-Tyr”]octreotide binding and internalization 
seems unlikely to be caused by de ~zuuo synthesis of SS-R, 
because this increase occurred within several minutes of 
incubation with 1 nM unlabeled octreotide. Therefore, the 
most likely explanation for this phenomenon is a rapid re- 
cruitment of cellular SS-R to the outside of the cell membrane, 
although an increased internalization rate or an effect of 
octreotide on SS-R synthesis cannot be fully excluded. In this 
respect, it should be mentioned that glucose has been shown 
to increase the amount of internalized SS in pancreatic islets, 
probably due in part to the increase in the cell surface SS-R 
concentration by migration of the secretion vesicles during 
emiocytosis, promoting increased transport of SS-R (33). 
Short term pretreatment of AtT20 cells with 1 nM octreotide 
did not result in a significant change in the estimated K, of 
[‘2”I-Tyr”]octreotide binding (our unpublished observation), 
indicating that the increased internalization is not caused by 
an augmented affinity of the receptor. 
Recently, at least five different SS-R subtypes have been 
cloned. All subtypes bind SS-14 and SS-28 with high affinity, 
whereas their affinities for numerous SS analogs differ con- 
siderably (34-39). Octreotide binds with high affinity to the 
human SSTR2 (hSSTR2) subtype, whereas this analog has a 
moderate affinity to hSSTR3 and hSSTR5 subtypes and 
shows no binding to the hSSTR subtypes 1 and 4 (34-39). 
More than one hSSTR subtype is expressed in human GH- 
secreting adenomas. Greenman and Melmed (40,41) showed 
in 3 of 7, 9 of 10, 6 of 7, 0 of 11, and 10 of 11 human 
GH-secreting adenomas, expression of hSSTR1, hSSTR2, 
hSSTR3, hSSTR4, and hSSTR5, respectively. In addition, 
Reubi et al. (42) recently demonstrated in GH-secreting ad- 
enomas, by in sittl hybridization autoradiography, hSSTR2 (7 
of 7 cases) and hSSTR3 (3 of 7), but not hSSTR1, expression. 
In all cases, binding of [‘2”I-Tyr”]octreotide and [‘2”I-Leu8, 
pTrp,'2; Tyr'~iSS-2a-,*as~iounri-i42); i~-ktT~~'cei&s; four-- 
SSTR genes (subtypes 1,2,4, and 5) are expressed, of which 
SSTR2 expression predominates (43). At present, it is unclear 
which SSTR subtype is involved in receptor-mediated en- 
docytosis by human GH-secreting adenoma and AtT20 cells. 
Bruno and Berelowitz (44) recently demonstrated that 
chronic SS exposure of GH, cells increased specific [12’1- 
Tyr”]SS binding, whereas SS also increased SSTRl-5 mes- 
senger RNA (mRNA) expression in these cells. Although 
SSTRl, -3, -4, and -5 mRNA increased after 6-48 h of expo- 
sure to SS, SSTR2 mRNA showed a biphasic response, ini- 
tially increasing at 2 h, then decreasing at 6 h, and achieving 
normalization by 48 h. These data suggest that the increased 
binding and internalization of [ ‘2”I-Tyr’]octreotide after 4 h 
of exposure to unlabeled octreotide may also be caused by an 
increase in SSTR2 subtype expression in AtT20- and human 
GH-secreting adenoma cells. Studies on internalization of 
[‘251-Tyr”]octreotide by cell lines stably expressing SSTR sub- 
types may help to answer this question. If  the SSTRl and 
SSTR4 subtypes, to which octreotide does not bind, also 
show ligand-induced internalization, SS analogs with high 
affinity to these SSTR subtypes may be of interest for radio- 
therapeutical application as well. However, such analogs are 
not available for clinical use at present. 
Our observation of a higher amount of binding and in- 
ternalization of [‘251-Tyr”]octreotide when the cells are si- 
multaneously incubated with a low concentration of unla- 
beled octreotide may explain the results of a recent in viva 
study by our group, in which we found that uptake of [“‘In- 
DTPA-o-Phe’loctreotide in SS-R positive organs (pituitary, 
pancreas, and adrenals) in rats showed a bell-shaped func- 
tion of the injected mass (18). Therefore, the highest specific 
radioactivity may not automatically result in the highest 
binding and subsequent internalization of the radioligand by 
the tumor in in viva SS-R imaging using radiolabeled SS 
analogs in patients with SS-R-positive tumors. Indeed, pre- 
liminary findings in patients indicate that scintigra’phy with 
a specific activity higher than 220 megabecquerels ’ ‘In/5 PLg 
[DTPA-o-Phe’loctreotide will lead to decreased quality, and 
uptake in tumors will be significantly reduced (45). More- 
over, Dorr et nl. (46) recently demonstrated an improved 
visualization of carcinoid liver metastases in patients by 
[“‘In-DTPA-~Phe’loctreotide during octreotide treatment, 
which might be due to up-regulation of SS-R by octreotide. 
Finally, it should be mentioned that we have used [12’1- 
Ty?]octreotide as a radioligand in our study. It has yet to be 
established, however, whether radiolabeled DTPA-conju- 
gated SS analogs, such as [“‘In-DTPA-n-Phe’loctreotide, are 
internalized by SS-R-positive tumor cells to the same extent 
as non-DTPA-coupled SS analogs. 
In conclusion, a high amount of [‘2sI-Tyr”]octreotide is 
internalized in a specific time-, temperature-, and pertussis 
toxin-sensitive GTP-binding protein-dependent manner by 
mouse AtT20 cells and human GH-secreting pituitary tumor 
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cells. The amount of internalized [‘2”I-Tyr”]octreotide by the 
human GH-secreting adenoma cell cultures correlated well 
with their in vivo and in vitro responsiveness of GH secretion 
to octreotide. Simultaneous incubation with a low concen- 
tration of unlabeled octreotide induces a very rapid increase 
in membrane binding and in the amount of internalization of 
[‘2”I-Tyr”]octreotide by AtT20 cells. Five of six human GH- 
secreting adenoma cell cultures also responded to unlabeled 
octreotide with an increase in the amount of internalized 
radioligand. It remains to be established, however, whether 
our present conclusions also apply to other types of human 
SS-R-positive neuroendocrine tumors. 
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